A look back at a transformative year for pharma
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
How CSOs can look to the future to forge successful relationships with pharma
Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen
The implications of adalimumab’s European patent expiry
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for experimental multiple sclerosis (MS) drug diroximel fumarate.
18th December 2018
Havas Lynx Group has created as many as 60 new jobs with its largest ever recruitment drive.
18th December 2018
Health and Social Care secretary Matt Hancock has announced that £1 billion of funding will go to as many as 75 projects across England to upgrade facilities and treat more patients, including mental health and new integrated care services in the community.
18th December 2018
The British Medical Association (BMA) has reported that private consultancy firms have been paid at least £26 million by the NHS as part of plans to reorganise the health service.
18th December 2018
The Prescription Medicines Code of Practice Authority (PMCPA) has announced that Astellas, Sunovion and Shield Therapeutics have all breached the Association of the British Pharmaceutical Industry's Code of Practice.
18th December 2018
Excitement around the transformative potential of AI and machine learning continues to build. Companies will need to adapt their individual offers to draw in AI specialists, but as an industry UK pharma should also continue to champion itself and the unique career advantages it holds for the best and brightest researchers.
Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government's second sector deal for the life sciences industry.
Mark Toms, chief scientific officer at Novartis Pharmaceuticals UK, looks at how to address the challenges of recruiting for Alzheimer’s prevention studies.
There are around 7,000 rare diseases for which there currently exists no authorised or satisfactory method of treatment, highlighting a vast area of unmet need, and yet the clinical development of orphan drugs is still fraught with many practical challenges.
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
This year pharma began to turn its eye towards the power of the microbiome
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
The true impact of biosimilars is starting to be felt across the industry
...But this year its impact, and the potential for change, was felt across the pharma industry
The biggest cases of the past year
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
Ashfield wants to change the perception of CSOs and their role within pharma
The one consistent theme in today’s market place is complexity
Many of us recognise that we need others’ knowledge to address the opportunities and challenges we face, yet we still lack the time or motivation to collaborate
The connectivity made possible by the Internet of Things (IoT) has provided new opportunities for businesses to put their buildings to work and reap the rewards
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
